|Articles|July 31, 2017

LabCorp to Acquire Chiltern for Approximately $1.2 Billion

LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients
September 12th 2025
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025

Trending on Applied Clinical Trials Online

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

© 2025 MJH Life Sciences^®

All rights reserved.